Buckley Wealth Management LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Buckley Wealth Management LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 0.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 153,564 shares of the biopharmaceutical company’s stock after selling 660 shares during the quarter. Pfizer accounts for about 1.4% of Buckley Wealth Management LLC’s portfolio, making the stock its 18th biggest holding. Buckley Wealth Management LLC’s holdings in Pfizer were worth $4,261,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. GoalVest Advisory LLC boosted its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new stake in Pfizer during the 4th quarter worth $32,000. VisionPoint Advisory Group LLC boosted its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new stake in Pfizer during the 4th quarter worth $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new stake in Pfizer during the 4th quarter worth $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $35.86.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.12 during trading hours on Friday, hitting $27.92. 11,067,424 shares of the company were exchanged, compared to its average volume of 40,730,523. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average of $27.81 and a 200-day moving average of $27.69. The stock has a market capitalization of $158.21 billion, a price-to-earnings ratio of -467.09, a P/E/G ratio of 1.08 and a beta of 0.70.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.23 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.02%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.